Invention Grant
- Patent Title: Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
-
Application No.: US15738467Application Date: 2016-06-29
-
Publication No.: US11059880B2Publication Date: 2021-07-13
- Inventor: Michael S. Kuhns , Thomas Serwold
- Applicant: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA , JOSLIN DIABETES CENTER, INC.
- Applicant Address: US AZ Tucson; US MA Boston
- Assignee: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA,JOSLIN DIABETES CENTER, INC.
- Current Assignee: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA,JOSLIN DIABETES CENTER, INC.
- Current Assignee Address: US AZ Tucson; US MA Boston
- Agency: Nguyen Tarbet LLC
- International Application: PCT/US2016/040177 WO 20160629
- International Announcement: WO2017/004252 WO 20170105
- Main IPC: C07K14/74
- IPC: C07K14/74 ; C07K14/725 ; C07K14/705 ; A61K35/17 ; C12N5/0783 ; C12N9/12

Abstract:
Chimeric receptors featuring major histocompatibility molecules grafted onto T cell receptor molecules and surrogate co-receptors featuring cell surface receptor ligands fused with signaling molecule domains. The chimeric receptors can be used to redirect cells, altering their specificity. T cells expressing chimeric receptors may bind to ICRs of target T cells for which their chimeric receptors are specific. Surrogate co-receptors may be used to help enhance TCR-CD3 signaling as part of this modular receptor system. The chimeric receptors and surrogate coreceptors may be used to help eliminate autoreactive T cells or program T cells to desired effector functions.
Public/Granted literature
- US20180179260A1 REDIRECTED CELLS WITH MHC CHIMERIC RECEPTORS AND METHODS OF USE IN IMMUNOTHERAPY Public/Granted day:2018-06-28
Information query